Dapagliflozin for Chronic Kidney Disease (ZENITH-CKD Trial)

"The data hosted on clinicaltrials.gov attests to this trial's ongoing recruitment of candidates, which was initiated on April 28th 2021 and most recently edited on November 22nd 2022."

"That is correct. According to the clinicaltrials.gov database, recruitment for this medical trial began on April 28th 2021 and it was last updated on November 22nd 2022. The study requires 495 participants dispersed across 62 different sites."

"Dapagliflozin is commonly prescribed for pharmaceutical preparations and can also aid patients with dietary issues, exercise limitations, or who have had minimal success with monotherapy."

"This clinical trial is seeking 495 adults suffering from renal disorders with an eGFR CKD-EPI score of ≥ 20 mL/min/1.73 m^2 and a UACR between 150–5000 mg albumin/g creatinine, based on single morning void spot urine sample collected at the time of screening. Furthermore, no SGLT2i or fixed dose SGLT2i combination treatments should have been received within one month prior to screening; ACEi, ARB, MRA doses must be steady for four weeks preceding the initial assessment; no cytotoxic therapy, immunosuppressive"

"The University of Texas Health Science Center at San Antonio first tested dapagliflozin in 2014 and, since then, 18462 studies have come to completion. Presently, 63 clinical trials are accepting enrollments with many situated in Toronto."

"Since 2014, AstraZeneca has been studying and sponsoring trials for the drug dapagliflozin. The first trial of 700 participants was completed that year with subsequent N/A approval granted afterwards. Currently there are 63 active medical studies across 235 cities in 50 countries."

"To participate in this study, patients should fall between 18 and 130 years of age. There are 46 trials available to minors while 517 studies target seniors above 65."

"Due to the lack of evidence regarding its efficacy, Dapagliflozin is rated at a 2 on the safety scale. This rating takes into account data collected during Phase 2 trials that point towards it being safe for use."

"This trial is currently enrolling participants across 62 different sites. Some of these are situated in Toronto, Winston-Salem and St. John's. It would be wise to select a location closest to you so that any travel required is kept to a minimum if chosen as part of the study."